Laura A. Solt

REV-ERBα/β Targeting Transcriptionally Reprograms HIV-Infected CD4+ T-Cells for Increased Viral Reactivation but Limited Virion Spread

This study shows that inhibiting REV-ERBβ increases HIV-1 reactivation in CD4+ T-cells but limits virion spread.

Selective Glucocorticoid Receptor Modulators of Immune Checkpoint Function

The paper develops selective glucocorticoid receptor modulators (SGRMs) that modulate immune checkpoint function by altering GR activity states through structural design and machine learning.

Negative regulation of TH17-mediated inflammation by the nuclear receptor REV-ERBβ

This study shows REV-ERBβ negatively regulates TH17-mediated inflammation in mouse models, acting independently from REV-ERB through distinct mechanisms.

Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials

This paper evaluates the safety and efficacy of SHP1705, a CRY2 activator, in preclinical models and Phase I trials, showing improved efficacy against GBM stem cells and synergistic effects with a REV-ERB agonist.

Structural basis for heme-dependent NCoR binding to the transcriptional repressor REV-ERBβ

The paper resolves conflicting findings on heme's role in REV-ERBβ-NCoR binding by showing heme directly enhances their interaction through structural and biochemical analyses.